METHODS OF THERAPY COMPRISING SIMULTANEOUS ADMINISTRATION OF METHOTREXATE AND FOLIC ACID
METHODS OF THERAPY COMPRISING SIMULTANEOUS ADMINISTRATION OF METHOTREXATE AND FOLIC ACID 5 Methotrexate (MTX) is an antineoplastic agent used the treatment of a wide variety of diseases including cancers and inflammatory autoimmune diseases such as psoriasis, Crohn's disease, and rheumatoid arthritis. Administered orally or by subcutaneous injection in low doses, MTX inhibits a number of folate dependent metabolic steps that lead to a state of effective folate 0 deficiency. It is likely that some of the adverse effects of MTX are due said folate deficiency, and the main factor affecting adherence to MTX is the occurrence of adverse effects, rather than lack of response. Although MTX side effects could be decreased by supplementation in folic acid (FA), the current guideline on folate administration is not precisely established. Now the inventors show that co-administration of MTX with FA on the same day is effective 5 compared to FA application one day after MTX. MTX metabolism was not affected, as demonstrated by the MTX-PG concentrations. The biological tolerance between the protocols was comparable. Thus, co-administration of MTX and FA seems to be possible and may be more convenient to the patients and improve compliance at the end..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 03. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
MÜLLER RÜDIGER [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-08-03, Last update posted on www.tib.eu: 2023-08-22, Last updated: 2023-08-29 |
|---|
| Patentnummer: |
WO2023144118 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA017856574 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA017856574 | ||
| 003 | DE-627 | ||
| 005 | 20230829134935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230818s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA017856574 | ||
| 035 | |a (EPA)WO2023144118 | ||
| 035 | |a (EPA)80446953 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a MÜLLER RÜDIGER |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a METHODS OF THERAPY COMPRISING SIMULTANEOUS ADMINISTRATION OF METHOTREXATE AND FOLIC ACID |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-08-03, Last update posted on www.tib.eu: 2023-08-22, Last updated: 2023-08-29 | ||
| 520 | |a METHODS OF THERAPY COMPRISING SIMULTANEOUS ADMINISTRATION OF METHOTREXATE AND FOLIC ACID 5 Methotrexate (MTX) is an antineoplastic agent used the treatment of a wide variety of diseases including cancers and inflammatory autoimmune diseases such as psoriasis, Crohn's disease, and rheumatoid arthritis. Administered orally or by subcutaneous injection in low doses, MTX inhibits a number of folate dependent metabolic steps that lead to a state of effective folate 0 deficiency. It is likely that some of the adverse effects of MTX are due said folate deficiency, and the main factor affecting adherence to MTX is the occurrence of adverse effects, rather than lack of response. Although MTX side effects could be decreased by supplementation in folic acid (FA), the current guideline on folate administration is not precisely established. Now the inventors show that co-administration of MTX with FA on the same day is effective 5 compared to FA application one day after MTX. MTX metabolism was not affected, as demonstrated by the MTX-PG concentrations. The biological tolerance between the protocols was comparable. Thus, co-administration of MTX and FA seems to be possible and may be more convenient to the patients and improve compliance at the end. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a MAROTTE HUBERT |4 aut | |
| 700 | 0 | |a DALIX ELISA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 03. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:03 |g month:08 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/80446953/publication/WO2023144118A1?q=WO2023144118 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 03 |c 08 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 03 |c 08 | ||